We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Roche Constructs Diagnostics Facility Near Munich

By LabMedica International staff writers
Posted on 06 Oct 2008
Roche (Basel, Switzerland) is investing US$190 million at its site in Penzberg, near Munich, Germany. More...
The money will be used to construct a multi-purpose building for Roche Diagnostics. The new building will be known as the Diagnostics Operations Complex (DOC) and will have a total floor area of 30,400 square meters. The complex consists of a central six-storied laboratory building with a basement flanked by two single-storied factory halls for the production units.

The building will house laboratories and production facilities for the Roche Applied Science and Roche Professional Diagnostics business areas. From about the middle of 2010, the complex will be manufacturing products ranging from biotech constituents for immunodiagnostics and the life-science market through to complete immunodiagnostic test kits. These test kits are used worldwide in diagnostic systems such as Cobas and Elecsys.

One of Roche's important markets is immunodiagnostics, which includes heterogeneous tests such as the cardiac markers NT-proBNP for acute and chronic heart failure and troponin T for myocardial infarction. Roche's immunologic tests are used by physicians for a variety of other applications, such as checking thyroid function, determining tumor markers, detecting infectious diseases such as hepatitis and human immunodeficiency virus (HIV), or helping to verify the effectiveness of drug-based therapy.

"In recent years, we have been successful in continuously expanding and marketing our range of immunodiagnostic tests,” said Jürgen Schwiezer, CEO of Roche's Diagnostics Division. "We are systematically pushing forward our activities in this interesting growth market by strengthening our capacity and capabilities in the research, development, and production of diagnostics constituents and tests. Against this background, the investment marks an important step in enhancing our leading position in the immunodiagnostics segment.”

Roche is an innovator of products and services for the prevention, early detection, diagnosis, and treatment of diseases. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and a market leader in virology.

Related Links:
Roche


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.